Boston Scientific (BSX Quick QuoteBSX - Free Report) reported $5.14 billion in revenue for the quarter ended September 2026, representing a year-over-year increase of 1.4%. EPS of $0.73 for the same period compares to $0.75 a year ago.

The reported revenue represents a surprise of +0.68% over the Zacks Consensus Estimate of $5.1 billion. With the consensus EPS estimate being $0.73, the company has not delivered EPS surprise.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Boston Scientific performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Geographic Revenue- Rest of the World: $1.83 billion compared to the $1.84 billion average estimate based on two analysts. The reported number represents a change of +3.3% year over year.
• Geographic Revenue- U.S.: $3.31 billion versus the two-analyst average estimate of $3.22 billion. The reported number represents a year-over-year change of +0.5%.
• Net Sales- Cardiovascular- Worldwide: $3.41 billion versus $3.32 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +1.9% change.
• Net Sales- MedSurg- Worldwide: $1.73 billion versus the four-analyst average estimate of $1.75 billion. The reported number represents a year-over-year change of +0.6%.
• Net Sales- MedSurg- Urology- Worldwide: $661 million compared to the $667.93 million average estimate based on three analysts. The reported number represents a change of -3.1% year over year.
• Net Sales- MedSurg- Endoscopy- Worldwide: $741 million versus the three-analyst average estimate of $756.7 million. The reported number represents a year-over-year change of -0.8%.
• Net Sales- MedSurg- Neuromodulation- Worldwide: $331 million versus $308.03 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +13% change.
• Net Sales- Cardiovascular- Interventional Cardiology & Vascular Therapies- Worldwide: $1.27 billion versus the two-analyst average estimate of $1.19 billion. The reported number represents a year-over-year change of +85.6%.
• Net Sales- Cardiovascular- Cardiac Rhythm Management (CRM)- Worldwide: $568 million versus $545.12 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -1.7% change.
• Net Sales- Cardiovascular- Watchman- Worldwide: $482 million versus the two-analyst average estimate of $449.61 million. The reported number represents a year-over-year change of -5.9%.
• Net Sales- Cardiovascular- Electrophysiology- Worldwide: $816 million versus $801.01 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -5.7% change.
• Net sales- Interventional Oncology & Embolization- Worldwide: 267.00 2 compared to the 263.67 2 average estimate based on two analysts.

View all Key Company Metrics for Boston Scientific here>>>

Shares of Boston Scientific have returned +2.7% over the past month versus the Zacks S&P 500 composite's -0.2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.